Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of GS-5745 in adults with cystic fibrosis
2015-002192-23Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of andecaliximab in cystic fibrosis (CF), sponsored by Gilead Sciences. Primary endpoint: Change in pre-bronchodilator FEV1 percent predicted at Week 8. Started May 2016; status: terminated.
02
Drugs
andecaliximab
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-002192-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002192-23.